Curasight Announces Encouraging Preliminary Data from Phase 1 Trial Evaluating First-in-Class Radiopharmaceutical uTREAT in High-Grade Gliomas®
Clear uptake of uTREAT® in aggressive brain cancer (glioblastoma) Early data support the potential of first-in-class uPAR-targeted theranostic approach to…
Read More










